Cardiovascular & General
Elabela
Elabela was found in 2013 as a second, unsuspected signal at the receptor apelin already uses, and it turned out to be indispensable: an embryo that cannot make it does not build a normal heart or blood vessels. In adult mice with pressure-overloaded, failing hearts, continuous infusion of it suppressed muscle thickening, scarring and loss of pumping strength, and the effect disappeared entirely in mice bred without the receptor — about as clean as an animal causal argument gets. It has never been given to a human being. The corpus record for it is marked preclinical only.
Last updated
Mechanism
Binds and activates the apelin receptor (APJ), a G-protein-coupled receptor governing vascular tone and cardiac contractility.
Reported effects
What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.
- Cardiovascular research
- Renal function research
- Developmental biology context
Dosing on file unverified
No established human dose; animal: 10 nmol/kg/hr, 39 µg/kg/hr
Carried from a source that labels it unverified, and reproduced with that label attached. A record of what is reported, not a recommendation. No citation on this page establishes it.
Half-life, storage & sport
- Elimination half-life
- 13 min (mice) — study. Frontiers in pharmacology 2025; mice, the native ELA-21 peptide (the comparator to the Fc-ELA-21 fusion in the same sentence).
The half-life on file is 13 min, measured in mice. No dosing schedule could be read from this record, so the curve below is one dose drawn from the moment it is given. Nothing here says how often it is repeated.
The measurement is not human. It was made in mice, and small mammals clear peptides faster than people do — so this is the fastest plausible shape rather than the expected one.
The rise is not modelled and the axis is not a blood level. No absorption rate constant and no volume of distribution are on file, so each dose appears at full height the instant it is given, and the axis is percent of this compound's own peak.
Literature on file 5
-
review or editorial
Elabela in Lipid-Related Cardiometabolic Dysfunction: A Critical Narrative Review. graded on: indexed as "Review" - secondary literature, not a study — “Review”
-
review or editorial
The Apelin-APJ Axis in Heart Failure: Mechanistic Insights, Clinical Evidence, and Translational Challenges. graded on: indexed as "Review" - secondary literature, not a study — “Review”
-
in vitro
The chemokine receptor-like fourth extracellular loop of the apelin receptor differentially regulates apelin and elabela binding and signalling. graded on: site-directed mutagenesis with plasmon resonance and BRET assays — read from the abstract — “abstract review”
-
in vitro
Preeclampsia Diagnosis Using β-Hairpin Peptide for ELABELA Detection. graded on: peptide-mimetic binding assays for ELABELA detection — read from the abstract — “abstract review”
-
animal in vivo
Therapeutic potential of ELABELA in alleviating hereditary hypertrophic cardiomyopathy. graded on: an animal model — read from the indexed abstract — “mouse”
Notes unverified prose
No human clinical trials identified; animal models only; not for human use; No human clinical trials; preclinical
Not on file 9
8 of the 8 fields we track hold nothing on this record, and each says why. 1 further absence is named below. A blank field is a bug; a named absence is a finding.
- molecular weightnothing we hold supplies it
- molecular formulanothing we hold supplies it
- CAS registry numbernothing we hold supplies it
- PubChem identifiernothing we hold supplies it
- amino-acid sequencenothing we hold supplies it
- SMILES stringnothing we hold supplies it
- InChInothing we hold supplies it
- InChI keynothing we hold supplies it
- route of administrationnothing we hold supplies it
Each field links to every other record missing the same thing. The full ledger holds 765 gaps across 163 records.